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ABSTRACT
Aims: To determine the impact of self-
monitoring blood glucose (SMBG) strip use 
in patients with type 2 diabetes in the UK. 
Methods: The study period was April 1, 2004 
to July 31, 2005. Data from primary care was 
extracted from The Health Improvement 
Network database. Patients identified 
with diabetes and matching the inclusion 
criteria were defined as new users of SMBG, 
prevalent users, or non-users. Patients were 
also defined as treated with insulin, with 
oral agents (OA), or not pharmacologically 
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treated. Change in glycosylated hemoglobin 
(HbA1c) at baseline and after 12 months 
was compared. Results: 2559 patients met 
the inclusion criteria. For new users, HbA1c
fell by 0.59% (P=0.399) for those treated 
with insulin, 1.52% (P<0.001) for those 
treated with OA, and 0.51% (P<0.001) for 
no treatment. In prevalent users, changes 
were 0.31% (P<0.001), 0.34% (P<0.001), 
and 0.09% (P=0.456), respectively. In non-
users, changes were 0.28% (P=0.618), 0.42% 
(P<0.001), and an increase of 0.05% (P=0.043), 
respectively. A significant decrease in mean 
HbA1c was associated with increasing strip 
use in OA patients newly initiated on strips. 
Conclusion: This observational study showed 
a significant decrease in HbA1c for new users of 
SMBG treated either non-pharmacologically 
or with OA, and for prevalent users treated 
with insulin or OA. Reduced HbA1c with 
increasing strip use was observed but was 
only significant for OA-treated new users. 
This suggests that SMBG use has a role in 
the treatment of non-insulin treated patients 
with type 2 diabetes.
Keywords: blood glucose strips; self-monitoring; 
type 2 diabetes2 Diabetes Ther (2010)  1(1):1-9.
INTRODUCTION
The  importance  of  glycemic  control  for 
patients with type 2 diabetes has been well 
documented.1 Current guidance in both the 
UK and the US recommends the use of self-
monitoring  blood  glucose  (SMBG)  for  both 
insulin and non-insulin treated type 2 diabetes.2,3 
There is, however, continuing debate as to the 
role of SMBG in the management of patients 
with non-insulin treated type 2 diabetes.4,5
Data  from  randomized  controlled  trials 
are  both  confusing  and  contradictory, 
predominantly  due  to  differences  in  study 
design and the inability to measure the impact 
of SMBG use in isolation to different treatment 
and management change algorithms.6,7 Studies 
based  on  observational  data  are  equally 
inconsistent. A report based on the Fremantle 
Diabetes  Study  described  no  difference  in 
glycosylated hemoglobin (HbA1c) between those 
using SMBG and those who were not,8 whereas 
a study based in the United States showed a 
significant reduction in HbA1c for those patients 
newly initiated on SMBG and those patients 
already using strips treated with either insulin 
or oral hypoglycemic agents (OA).9 Furthermore, 
this study also demonstrated a significant dose 
response between frequency of SMBG usage and 
reduction in HbA1c.
There is a cost to providing SMBG,4  but 
this may prove cost-effective when improved 
management  is  offset  by  the  reduction  of 
diabetes-related complications.10 There have 
also been concerns about the potential negative 
psychological impact upon patients of using 
SMBG.11,12 However, this has been countered 
with claims that the use of SMBG allows for the 
empowerment of patients and enables them to 
have a greater understanding of their condition 
and how it is affected by medication and their 
lifestyle choices. Nevertheless, SMBG use requires 
the patient and/or carer to act appropriately on 
the results, otherwise no benefit will accrue.
A previous cohort study by Karter et al.13 
sought to assess the longitudinal association 
between SMBG and glycemic control in diabetic 
patients  within  a  US  health  plan  (Kaiser 
Permanente, Northern California, USA). The 
study reported reductions in HbA1c for new users 
of SMBG, compared with non-users, although 
it was acknowledged that it did not control for 
dose escalation during the study period and, as 
such, could not isolate the impact of initiation 
of SMBG.
The aim of this study was to characterize 
patterns of SMBG use, treatment, and associated 
HbA1c values in patients with type 2 diabetes 
within a UK setting, based on the findings from 
the Karter Study.13
MATERIALS AND METHODS
Data Sources
Data used in this study were provided by The 
Health Improvement Network14 database, which 
is a longitudinal research database derived from 
over 350 primary care practices in the UK and has 
records for approximately 6 million patients.15
Inclusion Criteria
The study period was based on April 1, 2004 
to July 31, 2005. Patients included in the study 
were those with a diagnosis of type 2 diabetes 
recorded in their medical history using the Read 
Code classification between 2002 and 2007, 
and a HbA1c test result recorded in the 90 days 
(inclusive) before baseline and the final quarter 
of the study period (between 273-365 days after 
baseline). For patients using SMBG, baseline 
HbA1c  was  defined  as  the  date  of  the  first 
prescription during the study period. For non-Diabetes Ther (2010)  1(1):1-9. 3
strip users, baseline was defined arbitrarily as the 
December 1, 2004.
Only  patients  prescribed  the  same 
combinations and dosages of oral and/or insulin 
treatment in the quarter before baseline and final 
quarter were included. Patients were excluded if 
they had a history of end-stage renal failure or 
a test result of serum creatinine ≥200 μmol/L 
recorded in their patient history.
Cohort Definitions
Patients were classified by SMBG use according 
to the nomenclature defined by Karter et al.,13 
based upon British National Formulary codes 
recorded in the patient’s prescription records. 
“Prevalent users” were those with at least one 
strip prescription before baseline date, and at 
least two separate prescriptions during the study 
period. “New users” were those with at least two 
separate prescriptions in the study period and 
no strips prescribed in the year before baseline. 
“Non-users” were those with no SMBG strips 
prescribed either before baseline or during the 
study period.
Patients were also classified according to 
therapy  regimen  based  upon  prescription 
records using the British National Formulary 
definitions. The “no medication” group were 
those patients with no prescriptions (either 
insulin or OA) recorded in the 90 days before 
baseline and the final quarter of the study. “OA” 
(oral agents only) were those patients prescribed 
at least one OA and no insulin prescription in 
the 90 days before baseline and the final quarter 
of the study. The “insulin” group were those 
patients prescribed at least one insulin agent, 
either on its own or in combination with OA at 
the quarter pre-baseline and the final quarter of 
the study period. Patients changing their total 
insulin dosage or OA dosage between these 
periods were excluded.
Statistical Analysis
Changes in mean HbA1c before and 12-months 
post-baseline were compared using the paired 
t-test. To evaluate the change in HbA1c associated 
with different volumes of strips use, mixed-
effects multi-level models were created that 
allowed for the change in HbA1c to be analyzed at 
multiple hierarchical levels, that is: strip category 
(<0.5/0.5-1/>1), age, sex, duration of diabetes, 
baseline HbA1c, and primary care practice. Due 
to the relatively small number of patients in 
the insulin groups when disaggregated by strip 
frequency, this analysis was restricted to those 
patients treated either with oral agents or who 
were not receiving pharmacological intervention. 
The variables were assumed to stand behind the 
fixed effects, whereas random effects were put 
on the primary care variable.
RESULTS
From a total of 31,667 patients with type 2 
diabetes, 2559 (8.1%) met the inclusion criteria 
as shown in Figure 1.
Demographic  characteristics,  duration  of 
diabetes, baseline HbA1c, and mean daily SMBG 
strip usage by therapy type and SMBG use is 
shown in Table 1. For each treatment group (no 
treatment, OA, and insulin), baseline HbA1c was 
higher for patients newly initiated on SMBG 
compared  with  non-users/prevalent  users, 
although this was only significant for the OA 
group (P<0.001). It was lowest for those patients 
who were non-users of SMBG. The new user 
groups were also younger with a shorter duration 
of diabetes.
SMBG was most commonly used by patients 
treated with insulin (n=271), of which 98.5% of 
these patients were either new or prevalent users. 
Conversely, it was least common in those who 
were receiving no medication (n=293 [29.8%]).4 Diabetes Ther (2010)  1(1):1-9.
Figure 1. Derivation of study cohort and grouping by self-monitoring blood glucose usage and treatment regimen. 
HbA1c=glycosylated hemoglobin; OA=oral agents.
Patients with 
diabetes 
n=31,667
Exclusions 
n=29,108
Cohort 
n=2559
No pre and post 
HbA1c 
n=27,226
Renal failure/
creatinine ≥200 
n=82
￿erapy change 
n=1800
OA 
n=1345
Insulin 
n=271
No medication
n=983
Prevalent user 
n=450
Prevalent user 
n=246
Prevalent user 
n=57
New user 
n=366
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n=21
New user 
n=236
Non-user 
n=529
Non-user 
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Figure 2. Change in mean baseline HbA1c for patients by self-monitoring blood glucose use and treatment. *P<0.001. 
†P<0.05. HbA1c=glycosylated hemoglobin; OA=oral agents.
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Change in HbA1c
Figure 2 shows the change in HbA1c before 
and after baseline by treatment type and SMBG 
use. For new users, HbA1c fell by 0.59% (P=0.399) 
for those patients treated with insulin, 1.52% 
(P<0.001) for those patients treated solely by OA, 
and 0.51% (P<0.001) for those patients receiving 
no treatment. In the prevalent users, HbA1c fell 
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Figure 3. Change in HbA1c between baseline and 
12 months by treatment group and daily self-monitoring 
blood glucose use in newly initiated patients. *P<0.05. 
HbA1c=glycosylated hemoglobin; OA=oral agents.
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Figure 4. Change in HbA1c between baseline and 
12 months by treatment group and daily self-monitoring 
blood glucose use in prevalent patients. *P<0.05. 
HbA1c=glycosylated hemoglobin; OA=oral agents.
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by 0.31% (P<0.001) for those patients treated 
with insulin, 0.34% (P<0.001) for those patients 
treated solely by OA, and by 0.09% (P=0.456) for 
those patients receiving no treatment.
In the non-user group, HbA1c fell by 0.28% 
(P=0.618) for those patients treated with insulin, 
0.42% (P<0.001) for those patients treated solely 
with OA and increased by 0.05% (P=0.043) for 
those patients receiving no treatment.
Change Associated with SMBG Strip Use
Mean  SMBG  strip  use  for  insulin-treated 
patients was lower for newly initiated rather than 
prevalent SMBG users (1.24 versus 1.73 strips per 
day, P=0.010). For the OA group, mean strips 
used per day was 0.84 for new users, compared 
with 0.86 for prevalent users (P=0.689). For the 
non-medication group, the mean strips used per 
day was 0.69 for new users, compared with 0.74 
for prevalent users (P=0.628).
Figures 3 and 4 show the change in HbA1c 
associated with different volumes of strip use 
by treatment groups for newly initiated and 
prevalent strip users, respectively, for those 
patients receiving either oral treatment or no 
treatment after adjusting for age, sex, baseline 
HbA1c, and duration of diabetes in the fixed-
effects model.
There was a significant decrease in mean 
HbA1c associated with increasing strip use in 
those patients newly initiated on strips, for 
patients in the OA group using greater than 
1 strip per day. In the prevalent user groups there 
was a pattern of reduced HbA1c associated with 
increased strip use for both treatment groups, 
but this was not significant.
DISCUSSION
This study aimed to replicate and improve 
upon the US study by Karter et al.,13 which 
determined the impact of SMBG use upon 
HbA1c for both newly initiated and prevalent 
users. Unlike this previous study, we were able 
to limit our analysis to those patients whose 
medication remained constant over the study 
period. As in the Karter13 study, there was a 
decrease in HbA1c for all new users regardless of 
therapy regimen following initiation of SMBG, 
although this was not significant for those 
patients prescribed insulin. For prevalent users 
we showed a significant decrease for those 
using insulin and OA, although there was a 
pattern of reduced HbA1c with greater strip use 
in the non-pharmacologically treated group.
For patients not using SMBG, there was a 
significant decrease in HbA1c only in those 
patients prescribed OA. For patients who did 
not  receive  pharmacological  intervention, 
there was a significant increase in HbA1c. Whilst 
there was a pattern of reduced HbA1c with 
increasing strip use, this was only significant 
for new users on OA. It should also be noted 
that unlike the majority of insulin users, who 
will use a broadly consistent number of strips 
each day, patients on OA or diet and exercise 
may perform intermittent glucose profiling, 
where they would test four or more times a day 
for a week, and then not test for a period. The 
“dose response” in the OA group may therefore 
indicate a frequency of glucose profiling rather 
than an absolute number of tests per day.
This was an observational study based on 
treatment patterns observed in primary care. 
As such it offers a “real world” picture of the 
impact  of  SMBG  use  in  everyday  practice. 
However, we accept that as it did not have the 
randomization that would occur in a controlled 
trial there may have been differences between 
those patients prescribed SMBG and may have 
confounded our results. Such differences may 
include patient compliance and motivation 
and  physician  preference.  However,  unlike Diabetes Ther (2010)  1(1):1-9. 7
Karter,13 in this study we were able to compare 
patients who remained on the same therapy 
regimen before and after initiation of SMBG. 
Clearly, the motivation to initiate SMBG, either 
by the patient or physician, will be the need 
to maintain glycemic control and so may be 
accompanied by changes in therapy.
Karter et al.13  highlighted  the  potential 
for  reverse  causality  and  we  noted  similar 
observations in our study—notably that the 
non-SMBG patients had lower HbA1c at baseline 
than  new  users.  As  such,  poor  glycemic 
control may be the trigger for SMBG use with 
accompanying intensification of educational 
interventions. In both patients treated with 
OA and those managed by diet and exercise, 
new users of SMBG had higher HbA1c values 
than  the  non-user  groups,  suggesting  that 
prescribers had criteria (explicit or implicit) 
in determining when (and why) to initiate 
a  patient  on  to  SMBG.  Furthermore,  both 
groups  also  showed  a  significant  decrease 
in HbA1c following initiation of SMBG. One 
criticism of SMBG studies is that it cannot be 
determined to what extent initiation of strips 
was accompanied by educational interventions 
which  may  have  been  different  to  those 
received by non-users. It should, however, be 
acknowledged that SMBG use in itself is not 
a  therapeutic  intervention,  but  an  insight 
to glucose control. In that context it makes 
sense that a patient that is being “educated” 
to improve control of their diabetes might 
receive SMBG as a tool to provide awareness of 
glucose levels and therefore seen as part of that 
education. This raises the issue as the extent 
to which the patient uses the data afforded to 
them from their SMBG monitoring. It could 
potentially  be  the  process  of  testing  itself 
which by reinforcing the presence of diabetes 
to the patient leads to increased awareness of 
the need to maintain glucose control. This 
question, however, cannot be addressed by 
this study.
The implication that poor glycemic control 
is one potential trigger for SMBG fits with 
the recent National Institute for Health and 
Clinical Excellence clinical guidelines2 on 
the management of type 2 diabetes, where it 
recommends that SMBG be offered to persons 
newly diagnosed with type 2 diabetes only as 
an integral part of his or her self-management 
education.  Furthermore,  the  observation 
that patients do not routinely start SMBG 
until they start to lose glycemic control may 
partly explain the conflicting results revealed 
by clinical trials investigating the impact of 
SMBG  in  non-insulin  users.  For  example, 
patients in the Diabetes Glycemic Education 
and Monitoring (DiGEM) study,16  with  a 
mean HbA1c  at  baseline  of  approximately 
7.5%, observed no benefit from SMBG in non-
insulin treated patients, compared with the 
Auto-Surveillance Intervention Active (ASIA) 
study,17 reporting a mean baseline HbA1c of 
around 9%, which did observe a benefit.
This study demonstrated that SMBG use 
was associated with lower HbA1c in non-
pharmacologically  treated  patients  who 
were new users but not in prevalent users. 
This might indicate that SMBG is of benefit 
initially in informing the patient about his or 
her HbA1c levels and how this can be affected 
by a patient’s exercise and diet regimes. Over 
a longer time period, this may be limited 
either due to the reduced impact of diet and 
exercise to control HbA1c over time or perhaps 
changes in patients’ behavior after the initial 
“novelty”  of  monitoring  and  reacting  to 
HbA1c readings.
Whereas some guidelines are moving away 
from recommending SMBG use in patients 
not treated with insulin, this study, and that 
of Karter,13 may indicate that SMBG use in 8 Diabetes Ther (2010)  1(1):1-9.
some subgroups of non-insulin-using patients 
is beneficial, at least initially, as a means 
of allowing a patient to understand his or 
her condition and the impact of behaviors 
upon it.
CONCLUSION
This observational study showed a significant 
decrease in HbA1c for new users of SMBG treated 
either non-pharmacologically or with OA, and 
for prevalent users treated with insulin or OA. 
Reduced HbA1c with increasing strip use was 
observed, but was only significant for OA treated 
new users. This suggests that SMBG use has a role 
in the treatment of non-insulin-treated patients 
with type 2 diabetes.
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